BioScrip, Inc. provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care. It also offers home nursing products and services to patients suffering from chronic and acute medical conditions. The company offers its services at patient's homes, outpatient clinics, nursing facilities, physician's offices, and ambulatory infusion centers. It markets and sells its products and services through sales and marketing representatives, and payor relationships. The company was founded in 1993 and is based in Denver, Colorado.
Industry, Sector and Symbol
Industry Home health care services
Sub-IndustryHealth Care Services
SectorMedical
SymbolNASDAQ:BIOS
CUSIP09069N10
Phone720-697-5200
Debt
Debt-to-Equity Ratio-4.79
Current Ratio1.70
Quick Ratio1.30
Price-To-Earnings
Trailing P/E Ratio-6.52
Forward P/E Ratio-9.26
P/E GrowthN/A
Sales & Book Value
Annual Sales$817.19 million
Price / Sales0.45
Cash FlowN/A
Price / CashN/A
Book Value($0.66) per share
Price / Book-4.35
Profitability
EPS (Most Recent Fiscal Year)($0.44)
Net Income$-64,190,000.00
Net Margins-9.23%
Return on EquityN/A
Return on Assets-8.77%
Miscellaneous
Employees2,154
Outstanding Shares127,950,000
BioScrip (NASDAQ:BIOS) Frequently Asked Questions
What is BioScrip's stock symbol?
BioScrip trades on the NASDAQ under the ticker symbol "BIOS."
How were BioScrip's earnings last quarter?
BioScrip Inc (NASDAQ:BIOS) released its earnings results on Thursday, May, 10th. The company reported ($0.12) EPS for the quarter, missing the consensus estimate of ($0.11) by $0.01. The company earned $168.60 million during the quarter, compared to analyst estimates of $164.72 million. BioScrip's revenue for the quarter was down 22.6% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.18) earnings per share. View BioScrip's Earnings History.
When is BioScrip's next earnings date?
What price target have analysts set for BIOS?
4 analysts have issued 12-month price objectives for BioScrip's stock. Their predictions range from $3.25 to $4.00. On average, they expect BioScrip's share price to reach $3.5625 in the next twelve months. View Analyst Ratings for BioScrip.
Who are some of BioScrip's key competitors?
Who are BioScrip's key executives?
BioScrip's management team includes the folowing people:
- Mr. Daniel E. Greenleaf, CEO, Pres & Director (Age 53)
- Mr. Stephen M. Deitsch, Sr. VP, CFO & Treasurer (Age 46)
- Ms. Harriet Booker, Sr. VP & COO (Age 51)
- Mr. Alex Schott, Sr. VP of Strategic Operations & Interim Chief Accounting Officer (Age 48)
- Ms. Jody Kepler, Sr. VP, Chief Compliance Officer & Privacy Officer (Age 48)
Has BioScrip been receiving favorable news coverage?
Media headlines about BIOS stock have trended somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies negative and positive news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. BioScrip earned a daily sentiment score of 0.16 on Accern's scale. They also gave media stories about the company an impact score of 46.22 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are BioScrip's major shareholders?
BioScrip's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Venor Capital Management LP (11.45%), Gabelli Funds LLC (8.00%), BlackRock Inc. (5.18%), Diamond Hill Capital Management Inc. (3.16%), Wynnefield Capital Inc. (2.37%) and Millennium Management LLC (1.90%). Company insiders that own BioScrip stock include Coliseum Capital Management, L, Daniel E Greenleaf, Jeffrey M Kreger, Michael G Bronfein, R Carter Pate and Stephen Deitsch. View Institutional Ownership Trends for BioScrip.
Which institutional investors are selling BioScrip stock?
BIOS stock was sold by a variety of institutional investors in the last quarter, including Alta Fundamental Advisers LLC, California Public Employees Retirement System, Gabelli Funds LLC, UBS Group AG, Teton Advisors Inc., Wells Fargo & Company MN, Wynnefield Capital Inc. and Royal Bank of Canada. Company insiders that have sold BioScrip company stock in the last year include Coliseum Capital Management, L and Michael G Bronfein. View Insider Buying and Selling for BioScrip.
Which institutional investors are buying BioScrip stock?
BIOS stock was acquired by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Venor Capital Management LP, Millrace Asset Group Inc., Cambridge Investment Research Advisors Inc., GSA Capital Partners LLP, Diamond Hill Capital Management Inc. and Schwab Charles Investment Management Inc.. Company insiders that have bought BioScrip stock in the last two years include Daniel E Greenleaf, Jeffrey M Kreger, R Carter Pate and Stephen Deitsch. View Insider Buying and Selling for BioScrip.
How do I buy shares of BioScrip?
Shares of BIOS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is BioScrip's stock price today?
One share of BIOS stock can currently be purchased for approximately $2.87.
How big of a company is BioScrip?
BioScrip has a market capitalization of $364.66 million and generates $817.19 million in revenue each year. The company earns $-64,190,000.00 in net income (profit) each year or ($0.44) on an earnings per share basis. BioScrip employs 2,154 workers across the globe.
How can I contact BioScrip?
BioScrip's mailing address is 1600 BROADWAY SUITE 700, DENVER CO, 80202. The company can be reached via phone at 720-697-5200 or via email at [email protected]
MarketBeat Community Rating for BioScrip (BIOS)
MarketBeat's community ratings are surveys of what our community members think about BioScrip and other stocks. Vote "Outperform" if you believe BIOS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BIOS will underperform the S&P 500 over the long term. You may vote once every thirty days.
